Reviewed by Michael Gill, B. Sc.
4 Axial Spondyloarthritis Clinical Trials Near Me
Top Hospitals for Axial Spondyloarthritis Clinical Trials
Image of As0014 50062 in Arizona.
As0014 50062
Glendale
1Active Trials
0All Time Trials for Axial Spondyloarthritis
2022First Axial Spondyloarthritis Trial
Image of As0014 50052 in Arizona.
As0014 50052
Phoenix
1Active Trials
0All Time Trials for Axial Spondyloarthritis
2022First Axial Spondyloarthritis Trial
Top Cities for Axial Spondyloarthritis Clinical Trials
Image of Houston in Texas.
Houston
4Active Trials
Memorial Rheumatology /ID# 216311Top Active Site
Image of Phoenix in Arizona.
Phoenix
2Active Trials
As0014 50052Top Active Site
Axial Spondyloarthritis Clinical Trials by Phase of Trial
Phase 2 Axial Spondyloarthritis Clinical Trials
1Active Axial Spondyloarthritis Clinical Trials
1Number of Unique Treatments
1Number of Active Locations
Axial Spondyloarthritis Clinical Trials by Age Group
18+ Axial Spondyloarthritis Clinical Trials
4Active Axial Spondyloarthritis Clinical Trials
Most Recent Axial Spondyloarthritis Clinical Trials
Clinical Trial
Began Recruiting Date
Phase
Top Treatments for Axial Spondyloarthritis Clinical Trials
Treatment Name
Active Axial Spondyloarthritis Clinical Trials
All Time Trials for Axial Spondyloarthritis
First Recorded Axial Spondyloarthritis Trial
Bimekizumab
2
2
2019
Upadacitinib
1
1
2019
Drug order 2
1
1
2020

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 25th, 2021

Last Reviewed: October 13th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 van der Heijde D, Baraliakos X, Sieper J, Deodhar A, Inman RD, Kameda H, Zeng X, Sui Y, Bu X, Pangan AL, Wung P, Song IH. Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial. Ann Rheum Dis. 2022 Nov;81(11):1515-1523. doi: 10.1136/ard-2022-222608. Epub 2022 Jul 4. https://pubmed.ncbi.nlm.nih.gov/357884922 van der Heijde D, Baraliakos X, Sieper J, Deodhar A, Inman RD, Kameda H, Zeng X, Sui Y, Bu X, Pangan AL, Wung P, Song IH. Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial. Ann Rheum Dis. 2022 Jul 4. pii: annrheumdis-2022-222608. doi: 10.1136/ard-2022-222608. [Epub ahead of print] https://pubmed.ncbi.nlm.nih.gov/357884923 Deodhar A, Van den Bosch F, Poddubnyy D, Maksymowych WP, van der Heijde D, Kim TH, Kishimoto M, Blanco R, Duan Y, Li Y, Pangan AL, Wung P, Song IH. Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2022 Jul 30;400(10349):369-379. doi: 10.1016/S0140-6736(22)01212-0. https://pubmed.ncbi.nlm.nih.gov/35908570